Researchers estimated the lifetime risk of gastrointestinal cancer and associated mortality.
‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar
Regeneron might be ready for competition with its blockbuster drug Eylea, but it’s not clear that investors are. On Thursday morning, the biotech’s leadership fielded